Cytek Biosciences (CTKB) Competitors

Prothena (NASDAQ:PRTA) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, community ranking, institutional ownership, dividends and earnings.

Does the media favor PRTA or CTKB?

In the previous week, Prothena had 10 more articles in the media than Cytek Biosciences. MarketBeat recorded 17 mentions for Prothena and 7 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.65 beat Prothena's score of 0.41 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cytek Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer PRTA or CTKB?

Prothena presently has a consensus price target of $61.86, indicating a potential upside of 329.56%. Cytek Biosciences has a consensus price target of $9.17, indicating a potential upside of 49.54%. Given Prothena's higher probable upside, analysts plainly believe Prothena is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Cytek Biosciences	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility and risk, PRTA or CTKB?

Prothena has a beta of 0.16, indicating that its stock price is 84% less volatile than the S&P 500. Comparatively, Cytek Biosciences has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500.

Is PRTA or CTKB more profitable?

Cytek Biosciences has a net margin of -5.05% compared to Prothena's net margin of -98.86%. Cytek Biosciences' return on equity of -2.58% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-98.86%	-24.19%	-20.59%
Cytek Biosciences	-5.05%	-2.58%	-2.05%

Which has higher earnings & valuation, PRTA or CTKB?

Cytek Biosciences has higher revenue and earnings than Prothena. Cytek Biosciences is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$91.37M	8.48	-$147.03M	-$2.48	-5.81
Cytek Biosciences	$193.01M	4.09	-$12.15M	-$0.08	-76.62

Do insiders and institutionals hold more shares of PRTA or CTKB?

97.1% of Prothena shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 28.2% of Prothena shares are owned by insiders. Comparatively, 9.6% of Cytek Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer PRTA or CTKB?

Prothena received 585 more outperform votes than Cytek Biosciences when rated by MarketBeat users. Likewise, 70.43% of users gave Prothena an outperform vote while only 45.45% of users gave Cytek Biosciences an outperform vote.

Company	Underperform	Outperform
Prothena	Outperform Votes 605 70.43%	Underperform Votes 254 29.57%
Cytek Biosciences	Outperform Votes 20 45.45%	Underperform Votes 24 54.55%

Summary

Prothena and Cytek Biosciences tied by winning 9 of the 18 factors compared between the two stocks.